These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33374775)

  • 21. [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
    Scheel AH; Dietel M; Heukamp LC; Jöhrens K; Kirchner T; Reu S; Rüschoff J; Schildhaus HU; Schirmacher P; Tiemann M; Warth A; Weichert W; Fischer RN; Wolf J; Büttner R
    Pathologe; 2016 Nov; 37(6):557-567. PubMed ID: 27510417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors.
    Ohkuma R; Miura S; Muto S; Toyomasu Y; Fujimoto Y; Ieguchi K; Onishi N; Shimizu T; Watanabe M; Takayanagi D; Goshima T; Horiike A; Hamada K; Ariizumi H; Shimokawa M; Hirasawa Y; Ishiguro T; Suzuki R; Iriguchi N; Tsurui T; Mura E; Takenoshita S; Numajiri K; Okabe N; Yoshimura K; Tsuji M; Kiuchi Y; Yajima T; Ishida H; Suzuki H; Yamochi T; Kobayashi S; Tsunoda T; Wada S
    Front Immunol; 2023; 14():1260492. PubMed ID: 37790929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative study of quantitative immunohistochemistry and quantum dot immunohistochemistry for mutation carrier identification in Lynch syndrome.
    Barrow E; Evans DG; McMahon R; Hill J; Byers R
    J Clin Pathol; 2011 Mar; 64(3):208-14. PubMed ID: 21177748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
    Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
    Front Immunol; 2021; 12():798424. PubMed ID: 35145511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrating endobronchial ultrasound bronchoscopy with molecular testing of immunotherapy biomarkers in non-small cell lung cancer.
    Bozinovski S; Vannitamby A; Rangamuwa K; Aujla S; Wang H; Aloe C; Irving L; Leong TT; Steinfort DP
    Transl Lung Cancer Res; 2021 Jun; 10(6):2779-2787. PubMed ID: 34295677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer.
    Gagné A; Orain M; Ionescu D; Tsao MS; Joubert D; Joubert P
    Lung Cancer; 2020 Aug; 146():276-284. PubMed ID: 32593917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry.
    Duncan DJ; Scott M; Scorer P; Barker C
    PLoS One; 2019; 14(4):e0215393. PubMed ID: 30986253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation.
    Taube JM; Akturk G; Angelo M; Engle EL; Gnjatic S; Greenbaum S; Greenwald NF; Hedvat CV; Hollmann TJ; Juco J; Parra ER; Rebelatto MC; Rimm DL; Rodriguez-Canales J; Schalper KA; Stack EC; Ferreira CS; Korski K; Lako A; Rodig SJ; Schenck E; Steele KE; Surace MJ; Tetzlaff MT; von Loga K; Wistuba II; Bifulco CB;
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
    Ilie M; Khambata-Ford S; Copie-Bergman C; Huang L; Juco J; Hofman V; Hofman P
    PLoS One; 2017; 12(8):e0183023. PubMed ID: 28797130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.
    Lou SK; Ko HM; Kinoshita T; MacDonald S; Weiss J; Czarnecka-Kujawa K; Boerner SL; Yasufuku K; Tsao MS; Schwock J
    Acta Cytol; 2020; 64(6):577-587. PubMed ID: 32599583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer.
    Jasani B; Bänfer G; Fish R; Waelput W; Sucaet Y; Barker C; Whiteley JL; Walker J; Hovelinck R; Diezko R
    Diagn Pathol; 2020 Apr; 15(1):37. PubMed ID: 32303234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.
    Tsao MS; Kerr KM; Kockx M; Beasley MB; Borczuk AC; Botling J; Bubendorf L; Chirieac L; Chen G; Chou TY; Chung JH; Dacic S; Lantuejoul S; Mino-Kenudson M; Moreira AL; Nicholson AG; Noguchi M; Pelosi G; Poleri C; Russell PA; Sauter J; Thunnissen E; Wistuba I; Yu H; Wynes MW; Pintilie M; Yatabe Y; Hirsch FR
    J Thorac Oncol; 2018 Sep; 13(9):1302-1311. PubMed ID: 29800747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reading immunohistochemical slides on a computer monitor--a multisite performance study using 180 HER2-stained breast carcinomas.
    Nassar A; Cohen C; Albitar M; Agersborg SS; Zhou W; Lynch KA; Heyman ER; Lange H; Siddiqui MT
    Appl Immunohistochem Mol Morphol; 2011 May; 19(3):212-7. PubMed ID: 21475038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AutoIHC-Analyzer: computer-assisted microscopy for automated membrane extraction/scoring in HER2 molecular markers.
    Tewary S; Arun I; Ahmed R; Chatterjee S; Mukhopadhyay S
    J Microsc; 2021 Jan; 281(1):87-96. PubMed ID: 32803890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation.
    Keppens C; Dequeker EM; Pauwels P; Ryska A; 't Hart N; von der Thüsen JH
    Virchows Arch; 2021 May; 478(5):827-839. PubMed ID: 33275169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Digital image analysis of HER2 immunohistochemistry in gastric- and oesophageal adenocarcinoma: a validation study on biopsies and surgical specimens.
    Koopman T; de Bock GH; Buikema HJ; Smits MM; Louwen M; Hage M; Imholz ALT; van der Vegt B
    Histopathology; 2018 Jan; 72(2):191-200. PubMed ID: 28746978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer.
    Bankhead P; Fernández JA; McArt DG; Boyle DP; Li G; Loughrey MB; Irwin GW; Harkin DP; James JA; McQuaid S; Salto-Tellez M; Hamilton PW
    Lab Invest; 2018 Jan; 98(1):15-26. PubMed ID: 29251737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiplex immunofluorescence staining and image analysis assay for diffuse large B cell lymphoma.
    Lee CW; Ren YJ; Marella M; Wang M; Hartke J; Couto SS
    J Immunol Methods; 2020 Mar; 478():112714. PubMed ID: 31783023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.